Literature DB >> 26762111

Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation.

Qiang Zhang1, Meimei Wan2, Jinming Shi3, David A Horita4, Lance D Miller2, Timothy E Kute5, Steven J Kridel2, George Kulik6, Guangchao Sui7.   

Abstract

Yin Yang 1 (YY1) regulates both gene expression and protein modifications, and has shown a proliferative role in cancers. In this study, we demonstrate that YY1 promotes AKT phosphorylation at S473, a marker of AKT activation. YY1 expression positively correlated with AKT(S473) phosphorylation in a tissue microarray and cultured cells of breast cancer, but negatively associated with the distant metastasis-free survival of 166 breast cancer patients. YY1 promotes AKT phosphorylation at S473 through direct interaction with AKT, and the AKT-binding site is mapped to the residues G201-S226 on YY1. These residues are also involved in YY1 interaction with Mdm2, Ezh2, and E1A, and thus are designated as the oncogene protein binding (OPB) domain. YY1-promoted AKT phosphorylation relies on the OPB domain but is independent of either transcriptional activity of YY1 or the activity of phosphoinositide-3-kinases. We also determine that YY1-promoted mTORC2 access to AKT leads to its phosphorylation at S473. Importantly, a peptide based on the OPB domain blocks YY1 interaction with AKT and reduces AKT phosphorylation and cell proliferation. Thus, we demonstrate for the first time that YY1 promotes mTORC2-mediated AKT activation and disrupting YY1-AKT interaction by OPB domain-based peptide may represent a potential strategy for cancer therapy.
© The Author (2016). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS. All rights reserved.

Entities:  

Keywords:  AKT; OPB domain; Yin Yang 1; breast cancer; oncoproteins; phosphorylation

Mesh:

Substances:

Year:  2016        PMID: 26762111      PMCID: PMC5007621          DOI: 10.1093/jmcb/mjw002

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  50 in total

1.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.

Authors:  Guangchao Sui; Christina Soohoo; El Bachir Affar; Frédérique Gay; Yujiang Shi; William C Forrester; Yang Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 2.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

3.  Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein.

Authors:  Y Shi; E Seto; L S Chang; T Shenk
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

4.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

5.  The Akt pathway in human breast cancer: a tissue-array-based analysis.

Authors:  Shikha Bose; Sindhu Chandran; James M Mirocha; Namrata Bose
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

6.  Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27.

Authors:  Meimei Wan; Weiwei Huang; Timothy E Kute; Lance D Miller; Qiang Zhang; Heather Hatcher; Jingxuan Wang; Daniel B Stovall; Gregory B Russell; Paul D Cao; Zhiyong Deng; Wei Wang; Qingyuan Zhang; Ming Lei; Suzy V Torti; Steven A Akman; Guangchao Sui
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

7.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

Authors:  Lance D Miller; Johanna Smeds; Joshy George; Vinsensius B Vega; Liza Vergara; Alexander Ploner; Yudi Pawitan; Per Hall; Sigrid Klaar; Edison T Liu; Jonas Bergh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

8.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.

Authors:  M Sun; G Wang; J E Paciga; R I Feldman; Z Q Yuan; X L Ma; S A Shelley; R Jove; P N Tsichlis; S V Nicosia; J Q Cheng
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

9.  Yin Yang-1 inhibits tumor cell growth and inhibits p21WAF1/Cip1 complex formation with cdk4 and cyclin D1.

Authors:  Hideto Ishii; Mark D Hulett; Jian-Mei Li; Fernando S Santiago; Christopher R Parish; Levon M Khachigian
Journal:  Int J Oncol       Date:  2012-02-09       Impact factor: 5.650

10.  PcG recruitment by the YY1 REPO domain can be mediated by Yaf2.

Authors:  Frank Wilkinson; Heather Pratt; Michael L Atchison
Journal:  J Cell Biochem       Date:  2010-02-15       Impact factor: 4.429

View more
  11 in total

1.  Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT.

Authors:  Lu Zhao; Ran Li; Ye-Hua Gan
Journal:  Cell Death Dis       Date:  2018-07-03       Impact factor: 8.469

Review 2.  Targeting mTOR in Acute Lymphoblastic Leukemia.

Authors:  Carolina Simioni; Alberto M Martelli; Giorgio Zauli; Elisabetta Melloni; Luca M Neri
Journal:  Cells       Date:  2019-02-21       Impact factor: 6.600

3.  Nectandrin B-mediated activation of the AMPK pathway prevents cellular senescence in human diploid fibroblasts by reducing intracellular ROS levels.

Authors:  Hyun-Jin Jang; Kyeong Eun Yang; Won Keun Oh; Song-I Lee; In-Hu Hwang; Kyung-Tae Ban; Hwa-Seung Yoo; Jong-Soon Choi; Eui-Ju Yeo; Ik-Soon Jang
Journal:  Aging (Albany NY)       Date:  2019-06-14       Impact factor: 5.682

4.  The Protective Role of Yin-Yang 1 in Cardiac Injury and Remodeling After Myocardial Infarction.

Authors:  Yu Huang; Liangpeng Li; Hongmei Chen; Qiao Liao; Xiaoli Yang; Dezhong Yang; Xuewei Xia; Hongyong Wang; Wei Eric Wang; Lianglong Chen; Chunyu Zeng
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

5.  YY1 activates EMI2 and promotes the progression of cholangiocarcinoma through the PI3K/Akt signaling axis.

Authors:  Shuai Zhou; Kang Lin Qu; Jin Ang Li; Shi Lei Chen; Yi Gang Zhang; Chao Zhu; Hao Jin; Yong Wang; Qing Pang; Hui Chun Liu
Journal:  Cancer Cell Int       Date:  2021-12-21       Impact factor: 5.722

6.  YY1 Oligomerization Is Regulated by Its OPB Domain and Competes with Its Regulation of Oncoproteins.

Authors:  Shiyao Qiao; Wenmeng Wang; Cheng Yi; Qingqing Xu; Wenfei Wang; Jinming Shi; Daniel B Stovall; Dangdang Li; Guangchao Sui
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

7.  Yin Yang 1 regulates ITGAV and ITGB1, contributing to improved prognosis of colorectal cancer.

Authors:  Nami Sato; Nozomu Sakai; Katsunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Shigetsugu Takano; Gaku Ohira; Hisahiro Matsubara; Masayuki Ohtsuka
Journal:  Oncol Rep       Date:  2022-03-10       Impact factor: 3.906

8.  Disruption of YY1-EZH2 Interaction Using Synthetic Peptides Inhibits Breast Cancer Development.

Authors:  Cheng Yi; Guangyue Li; Wenmeng Wang; Yixuan Sun; Yueling Zhang; Chen Zhong; Daniel B Stovall; Dangdang Li; Jinming Shi; Guangchao Sui
Journal:  Cancers (Basel)       Date:  2021-05-16       Impact factor: 6.639

Review 9.  The biological implications of Yin Yang 1 in the hallmarks of cancer.

Authors:  Ian Timothy Sembiring Meliala; Rendy Hosea; Vivi Kasim; Shourong Wu
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

Review 10.  Biological roles of Yin Yang 2: Its implications in physiological and pathological events.

Authors:  Lang Li; Yanjun Li; Ian Timothy Sembiring Meliala; Vivi Kasim; Shourong Wu
Journal:  J Cell Mol Med       Date:  2020-09-23       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.